NeuroSense Therapeutics Ltd. Business Update and Financial Results for H1 2025

SEC Filing 6-K (0001213900-25-070315)

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) provided a business update and financial results for the first half of 2025. The company is advancing its investigational combination therapy, PrimeC, for amyotrophic lateral sclerosis (ALS) through regulatory pathways and preparing for a pivotal Phase 3 trial. Key highlights include regaining compliance with Nasdaq’s stockholders’ equity requirement, generating additional long-term data from the Phase 2b PARADIGM study, and scaling up manufacturing capabilities. Upcoming milestones for H2 2025 include submitting a new NOC/c request in Canada, commencing a multinational Phase 3 trial, and advancing a binding term sheet with a global pharmaceutical partner. Financial results for H1 2025 show a decrease in research and development expenses to $2.5 million, down from $3.7 million in H1 2024, and a net loss of $4.7 million. The company’s cash position as of June 30, 2025, was $666,000.